ADC Therapeutics SA
Filed with the SEC on · accession 0001628280-26-071899
ADCT filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -7.6% by the first close after the filing.
ADC Therapeutics SA announced its financial results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
Close before
$1.58
Nov 6, 2026
First close after
-7.59%
$1.46
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ADCT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ADCT?
Click hereADCT filed a 8-K (SEC filing). ADC Therapeutics SA announced its financial results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
ADCT closed at $1.58 before the filing and $1.46 on Nov 9, 2026 (-7.59%).
Get alerts when ADCT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days